Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 18/20 | 0.98 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.98 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL356225 | 1.00 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356224 | 1.00 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| SCHEMBL29416829 | 0.99 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL160102 | 0.99 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL220478 | 0.99 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069087 | 0.94 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069089 | 0.94 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| SCHEMBL4593663 | 0.91 | DPP4 (0.85) | DPP4DPP7DPP8 | |
| SCHEMBL665644 | 0.91 | DPP4 (0.85) | DPP4DPP7DPP8 | |
| SCHEMBL8245189 | 0.91 | DPP4 (0.85) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079469-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008057337-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | NOVARTIS AG (CH) | 2008-05-15 | — | — | WO | claimed |
| EP-1786401-B1 | FAST RELEASE COMPOSITION INCLUDING MELT GRANULES OF A MOISTURE SENSITIVE DRUG AND PROCESS FOR MANUFACTURING THEREOF | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-3087975-A1 | TREATMENT WITH VILDAGLIPTIN | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143217-B2 | Use of DPP-IV inhibitor to reduce hypoglycemic events | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2191824-B1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110245317-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | disclosed |
| US-7935723-B2 | Metformin and a dipeptidyl peptidase IV inhibitor such as vildagliptin; improving glucose control | NOVARTIS PHARMA AG (CH) | 2011-05-03 | — | — | US | disclosed |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | KOWALSKI JAMES | 2011-04-14 | — | — | US | disclosed |
| WO-2007006790-A2 | COMBINATION OF A DPP-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006135723-A2 | MODIFIED RELEASE 1-[(3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL]-PYRROLIDINE-2(S)-CARBONITRILE FORMULATION | NOVARTIS AG (CH) | 2006-12-21 | — | — | WO | disclosed |
| EP-1732550-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | Novartis AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006047248-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METFORMIN | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006041976-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006021455-A1 | FAST RELEASE COMPOSITION INCLUDING MELT GRANULES OF A MOISTURE SENSITIVE DRUG AND PROCESS FOR MANUFACTURING THEREOF | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006005613-A1 | COMBINATION OF DPP-IV INHIBITORS AND COMPOUNDS MODULATING 5-HT3 AND/OR 5-HT4 RECEPTORS | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005117861-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005079795-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | NOVARTIS AG (CH) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | MAST1, CACNG1, CMA1 | DPP4 267/4885DPP7 525/4885DPP8 1048/4885 |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | PPARG, DPP4, DPP3 | DPP4 2/4885DPP7 5/4885DPP8 7/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20110245317-A1 | USE OF ORGANIC COMPOUNDS | DPP4, DPP8, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.